&w=3840&q=100)
Zydus gets USFDA approval for a high blood pressure to treat angina
Press Trust of India New Delhi
Zydus Lifesciences on Monday said it has received approval from the US health regulator to market a drug used to treat angina and high blood pressure.
The company has received final approval from the US Food and Drug Administration (USFDA) for Diltiazem Hydrochloride tablets in strengths of 30 mg, 60 mg, 90 mg, and 120 mg, the drug maker said in a statement.
Diltiazem Hydrochloride Tablets are indicated for the management of chronic stable angina and angina due to coronary artery spasm.
It belongs to a class of drugs called calcium-channel blockers. Diltiazem works by relaxing blood vessels, which reduces the workload on the heart and increases blood and oxygen supply to the heart muscle.
The company said Diltiazem Hydrochloride Tablets will be produced at Zydus Lifesciences' Baddi plant in Himachal Pradesh.
As per IQVIA MAT June 2025 data, Diltiazem Hydrochloride Tablets had annual sales of $13.9 million in the US.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
an hour ago
- Hindustan Times
Doctor shares 10 daily foods that mimic Ozempic and make weight loss easier
Ozempic is not just a celebrity buzzword! It is a prescription drug originally developed to treat type 2 diabetes, now widely talked about for its surprising weight loss effects. This buzz has sparked curiosity about whether there are natural alternatives to Ozempic. The answer is yes! Dr Adrian, a functional medicine doctor and MD specializing in thyroid, PCOS, and gut health, recently shared on Instagram a list of foods that may work in a similar way. These foods can help boost GLP-1, the hormone that curbs unnecessary hunger and helps control appetite, supporting a healthy weight loss. Try these foods to naturally boost GLP-1 levels! (Adobe Stock) What is Ozempic? Ozempic is the brand name for semaglutide, a medication created by Danish drugmaker Novo Nordisk. It belongs to a class of drugs called GLP-1 receptor agonists, meaning it imitates the effects of a hormone your body naturally produces, GLP-1. First approved by the US Food and Drug Administration in 2017 for managing type 2 diabetes, Ozempic comes as a once-weekly injection, usually given in the abdomen, thigh, or upper arm using a prefilled pen. How does GLP-1 support weight loss? GLP-1 is an incretin hormone released in your gut after you eat. Health Shots also got in touch with dietitian Vidhi Chawla to learn more about it. She says, 'It triggers more insulin, curbs glucagon (which raises blood sugar), and slows digestion, all of which help keep blood sugar stable and reduce appetite.' That is why Ozempic is effective for weight loss. Foods to boost GLP-1 Here are 10 foods that may help make weight loss feel easier and quicker with an Ozempic prescription: 1. Avocados Packed with healthy monounsaturated fats and fibre, avocados keep hunger hormones in check. Dr Adrian notes that their slow-digesting fat content supports steady blood sugar, while the fibre helps keep you feeling full for longer. A study published in Nutrients revealed that eating a whole avocado can boost GLP-1 levels, along with reducing cravings and appetite. This food is also rich in potassium, which supports metabolism and slows down digestion. 2. Chia seeds These tiny seeds are a powerhouse of soluble fibre. When soaked, they form a gel in your stomach that slows digestion, much like Ozempic delays gastric emptying (the rate at which food moves from the stomach to the small intestine). Vidhi Chawla adds that chia seeds are also a good plant-based omega-3 source, supporting gut health and reducing inflammation linked to weight gain. 3. Potatoes Often misunderstood, potatoes (especially boiled or baked) are among the most satiating foods that can support weight loss. They provide slow-digesting carbs that keep energy stable. Dr Adrian points out that their resistant starch content feeds beneficial gut bacteria, which may indirectly support weight control. 4. Oats Oats, particularly rolled oats, are rich in beta-glucan, a soluble fibre that triggers fullness hormones. They are a steady energy source that reduces the risk of unwanted hunger. Vidhi recommends starting your day with oatmeal paired with protein, like Greek yogurt, for even better hunger control. According to her, fibre rich foods help reduce your calorie intake by promoting the feeling of fullness. Oats can support weight loss!(Adobe Stock) 5. Eggs and egg whites Eggs are loaded with protein that lowers ghrelin, the "I'm hungry" hormone. Their amino acids also support muscle maintenance during weight loss. Having them at breakfast can help curb appetite for hours, making them a simple yet effective tool in any weight-loss-friendly diet. So, make sure you start your day with a protein and fibre-rich breakfast to support weight loss. 6. Greek Yogurt Thick, creamy, and protein-rich, Greek yogurt is digested slowly, keeping you satisfied for longer. Its probiotic content supports gut health, which is linked to better weight management. Dr Adrian advises choosing unsweetened versions to avoid unnecessary sugar spikes. 7. Lean meat From skinless chicken to turkey, lean meats deliver high-quality protein that boosts metabolism due to the thermic effect of food. This means you burn more calories even when digesting food. Vidhi notes that protein also helps prevent the muscle loss often seen in rapid weight loss, keeping metabolism healthy. 8. Fish Fatty fish like salmon, mackerel, and sardines offer both protein and omega-3 fats. Dr Adrian says this combo reduces inflammation, balances hormones, and suppresses appetite. Eating fish 2–3 times a week can be a game-changer for promoting both satiety and metabolic health. 9. Berries Low in sugar but high in fibre, berries are ideal for controlling blood sugar spikes. Their antioxidants also help reduce inflammation, which can interfere with hunger and satiety signals. Vidhi suggests pairing berries with Greek yogurt for a balanced, filling snack. 10. Leafy greens Spinach, kale, broccoli, and other fibre-rich vegetables are filling yet low in calories. They fill your stomach, stimulate fullness hormones, and deliver vitamins that support overall metabolic function, explains Dr Adrian. One 2022 study published in the International Journal of Preventive Medicine found that eating vegetables before carbohydrates significantly improves glucose and GLP-1 levels in people with type 2 diabetes. What's more? Since they are also high in vitamins, minerals, and antioxidants, they can also help support healthy metabolism and the fat-burning process.
Time of India
4 hours ago
- Time of India
How a one-minute jolt can offer hope to those with auto-immune disease
The US Food and Drug Administration (FDA) approved a medical device recently that offers new hope to patients incapacitated by rheumatoid arthritis (RA), a chronic condition often resistant to treatment and usually managed with medications. The device represents a radical departure from standard care, tapping the power of the brain and nervous system to tamp down the uncontrolled inflammation that leads to the debilitating autoimmune disease. The SetPoint System is an inch-long device surgically implanted into the neck, where it sits in a pod wrapped around the vagus nerve, which some scientists believe is the longest nerve in the body. The device electrically stimulates the nerve for one minute each day. The stimulation can turn off crippling inflammation and 'reset' the immune system, research has shown. Most drugs used to treat rheumatoid arthritis suppress the immune system, leaving patients vulnerable to serious infections. On a recent episode of the American College of Rheumatology podcast, the SetPoint implant was described as a 'true paradigm shift' in treatment of the disease, which until now has relied almost entirely on an evolving set of pharmaceutical interventions, from gold salts to biologics. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like No annual fees for life UnionBank Credit Card Apply Now Undo The FDA designated the implant as a breakthrough last year to expedite its development and approval. It represents an early test of the promise of so-called bioelectronic medicine to modulate inflammation, which plays a key role in diseases including diabetes, heart disease and cancer. Clinical trials are already underway testing vagus nerve stimulation to manage inflammatory bowel disease in children, lupus and other conditions. Trials for patients with multiple sclerosis and Crohn's disease are also planned. In a yearlong randomised controlled trial of 242 patients that included a sham-treatment arm, over half of the participants using the SetPoint implant alone achieved remission or saw their disease recede. Measures of joint pain and swelling fell by 60% and 63% respectively. The device's long-term effectiveness and safety outside a clinical trial are not yet known. The FDA required post-marketing monitoring of patients and adverse events as part of the approval. Surgery involving implants can lead to serious infections resistant to antibiotics, experts noted. For Dawn Steiner, 58, a speech pathologist, who participated in the clinical trial, the implant has been a game changer. She was diagnosed with rheumatoid arthritis 15 years ago and has tried eight different biologic agents since then. 'Before the implant, the doctor would ask where I was in terms of pain on a scale of one to 10, and I would say I was living a six or seven,' she said. 'Now I'm about a two.' The SetPoint device is the product of decades of research spearheaded by Dr Kevin J Tracey, a neurosurgeon who is president and chief executive of the Feinstein Institutes for Medical Research at Northwell Health. Tracey co-founded SetPoint Medical, but now serves as an adviser. He describes the vagus nerve, which originates in the brain and travels to virtually all the organs of the body, as an 'on-off switch' for an overactive immune system. 'The brain can turn off inflammation as long as the vagus nerve is intact,' he said. 'It's like a brake system in your car.' Dr David Chernoff, chief medical officer of SetPoint Medical, said, 'Drugs find a pathway that contributes to damaging joints in RA patients and try to block it. What we're doing is completely different. We're re-educating the immune system through the brain to behave differently,' he added. As a result, he said, 'we're not blocking the ability to fight off infection.' The body needs some level of inflammation, Tracey said, to help heal wounds, fight infections and promote tissue repair. The price has not been disclosed, but a spokeswoman said it was designed to last for 10 years and would be less expensive than a year's worth of some rheumatoid arthritis drugs, which can be quite costly. One key question is whether the implant's effectiveness will wane over time, said Dr Lou Bridges, chief of the division of rheumatology at the Hospital for Special Surgery and NewYork-Presbyterian/Weill Cornell Medical Center. 'It's still early days. The proof will be in the pudding,' he said. 'I'm hoping they are correct, and this is a revolutionary new way to treat RA without drugs and without side effects. But I've heard this story before. ' nyt news service By: Dr David Chernoff, CMO, SetPoint Medical
News18
a day ago
- News18
What It Takes to Build an FDA-Approved Oncology Plant in India
The strategic, operational, and compliance playbook behind India's growing footprint in regulated cancer drug markets. India's pharmaceutical industry has earned its place as the world's largest supplier of generic medicines, with over 650 manufacturing facilities approved by the US FDA. This number positions India as the global custodian in generics. While this statistic is often cited to highlight scale, a more telling sign of maturity is the rising number of oncology plants built in India, not just to serve domestic markets but to meet the stringent regulatory standards of the US and EU. Among all drug categories, oncology manufacturing demands the most rigorous quality controls, cleanroom architecture, and data integrity systems. Building such a facility isn't a matter of scaling up what already exists. It's a fundamental shift in how a company thinks, plans, executes, and sustains compliance. The difference begins with the product itself. Oncology drugs, especially those based on highly potent APIs, cytotoxics, or monoclonal antibodies, require full containment, sophisticated air-handling systems, and precise zone separation. Even minor lapses in cross-contamination or validation can result in patient harm. Unlike standard oral generics, oncology formulations often involve sterile injectables, lyophilised powders, or targeted biologics. Each step in the process, from material handling to packaging, must be validated against international GMP standards. They must undergo installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ) validation and continuous environmental monitoring. These aren't mere upgrades to existing facilities. They are entirely new ecosystems built from the ground up. The journey of getting FDA Approval begins long before a brick is laid. The process begins with site selection. This plays a critical role, especially when waste handling and zoning compliance for hazardous materials are involved. Pharma hubs in Gujarat, Baddi, Telangana, and Maharashtra offer infrastructural advantages, but even here, environmental clearance, utility design, and HVAC zoning take months to finalise. The regulatory approvals run in parallel. Companies need to secure a state manufacturing license, followed by CDSCO approval and eventually, US FDA registration. In parallel, the design and construction teams work closely with quality and validation teams to establish protocols for cleanroom classification, air change rates, and water-for-injection (WFI) systems. Once construction is complete, validation begins with processes like IQ, OQ and PQ being run across all systems from HVAC to filling lines, and every deviation is documented and closed. This phase alone can stretch over six to nine months. In total, it can take two to three years from planning to inspection. This integrated effort demands not just technical competence but cultural alignment. Companies that invest early in staff training, data integrity systems, and audit simulations are typically better prepared for FDA scrutiny. Those that delay often face the issuance of Form 483, an inspectional observation report listing any conditions that may violate the Food, Drug, and Cosmetic Act. These findings range from incomplete batch records to deficiencies in aseptic processing and signal gaps in quality systems. As global inspections ramped up in recent times, foreign FDA drug inspections more than doubled from 130 in FY2021 to 262 in FY2022, where OAI outcomes have steadily declined, reflecting better inspection readiness and improved documentation culture. The returns, however, justify the effort. Once approved, the facility gives huge access to the US and European markets, where oncology drugs represent one of the fastest-growing therapeutic segments. Mr. Vishwa Savla, the Managing Director and CEO of Pinnacle Life Science, which got US FDA Approval last year, said in this context, 'We knew from the beginning that if we got this right, it would change the trajectory of our company. Of course, it's a high-stakes investment, but the payoff is clear. My team was sure that this would take time, but we knew that we were building our capability for a lifetime once the facility was operational. And it's needless to emphasise that if you're serious about oncology, you have to build to FDA standards. There's no shortcut to that. The oncology pipeline demands long-term thinking, and FDA approval gave us a foothold in markets where both quality and trust are non-negotiable." Ultimately, building an FDA‑licensed oncology plant in India demands capital, time, technical rigour, and cultural commitment. But with global oncology spending expected to exceed USD 375 billion by 2027, Indian companies that invest in compliance today are positioning themselves for long-term value not just commercially, but in terms of credibility and global impact. (Disclaimer: The above press release comes to you under an arrangement with NRDPL and PTI takes no editorial responsibility for the same.). PTI (This story has not been edited by News18 staff and is published from a syndicated news agency feed - PTI) view comments First Published: August 12, 2025, 12:00 IST News agency-feeds What It Takes to Build an FDA-Approved Oncology Plant in India Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
